Mondelez Q2 Margin Uplift Fails to Offset Cocoa Phasing, YTD Profit Still Pressured

What happened

Mondelez's Q2 2026 results showed a sequential improvement in gross margin, driven by productivity savings and carryover pricing, but the benefit was partially offset by still-elevated cocoa costs working through inventory. Year-to-date profitability and EPS remain under pressure because of unfavorable cocoa cost phasing from earlier in the year, consistent with the DeepValue assessment that input inflation is broader and more persistent than a simple cocoa shock. While the company has managed to pass through some costs via pricing, volume/mix remains negative globally, limiting the top-line contribution to profit recovery, as noted in the latest filings showing -3.2 points volume/mix in 9M 2025. The improvement in gross margin is a positive signal that cost actions are taking hold, but it is not yet enough to confirm a durable margin recovery given ongoing elasticity and tariff headwinds. Overall, the quarter supports the existing WAIT thesis: the earnings trough is bottoming, but the pace of recovery is too uncertain to warrant upgrading the stock at current levels.

Implication

The Q2 margin uplift confirms that management's productivity and pricing actions are providing some cushion, but it does not change the fundamental challenge of elevated cocoa costs and negative volume/mix. Given that year-to-date EPS is still pressured, the market may continue to discount the stock until there is clearer evidence of margin repair across multiple quarters without relying on further large price increases. The attractive entry price remains $47 per the DeepValue analysis, and current levels above $53 do not offer sufficient margin of safety relative to the bear case outcome of stalled EPS growth. Investors should monitor upcoming quarters for signs that volume/mix is stabilizing, particularly in North America and Europe, and that cocoa deflation is actually flowing through to the bottom line, not just being offset by pricing. Until then, the risk-reward is not asymmetric; waiting for either a lower price or stronger proof of earnings recovery will likely improve expected returns.

Thesis delta

The Q2 2026 margin improvement signals that cost actions are beginning to take hold, slightly increasing conviction in the eventual margin recovery, but it does not change the overall WAIT rating. Cocoa cost phasing and persistent volume/mix weakness continue to support the view that EPS growth may undershoot high-single-digit expectations, and the stock remains unattractive above $53 without clearer proof of volume stabilization. The thesis remains intact, with a possible upgrade if subsequent quarters show sustained margin expansion and volume improvement.